The U.S. beer industry has seen better days. Millennials, now the largest generational cohort, don't share their parents' affection for beer, and instead prefer hard spirits or wine. And Big Beer has fared worse than the overall industry, as drinkers are increasingly eschewing mass-market labels like Budweiser, Coors Light, and Bud Light in favor of craft brews.
The shift has weighed on the stocks of major brewers Anheuser Busch InBev and Molson Coors Brewing: Both companies have underperformed the market.
Data by YCharts.
Constellation Brands (NYSE:STZ) has taken a different approach. Last year, the company surprised investors by taking a stake in marijuana company Canopy Growth (NYSE:CGC), and recently doubled down on this investment. Are these the early signs of a major change in direction for the company?
Constellation throws green at Canopy GrowthIn October, Constellation Brands took a near-10% position in Canopy Growth, paying $191 million for its stake, which valued the company at nearly $2 billion. It was a controversial move, but CEO Rob Sands justified the investment by explaining that the company eventually expected nationwide marijuana legalization.
Hot Heal Care Stocks For 2019: American Woodmark Corporation(AMWD)
Advisors' Opinion:- [By Stephan Byrd]
Quadrature Capital Ltd acquired a new stake in shares of American Woodmark Co. (NASDAQ:AMWD) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,332 shares of the company’s stock, valued at approximately $525,000.
- [By Lisa Levin]
Friday morning, the industrial shares rose 0.42 percent. Meanwhile, top gainers in the sector included Deere & Company (NYSE: DE), up 5 percent, and American Woodmark Corporation (NASDAQ: AMWD) up 3 percent.
- [By Lisa Levin]
Shares of American Woodmark Corporation (NASDAQ: AMWD) got a boost, shooting up 14 percent to $100.60 after the company reported upbeat Q4 results.
- [By Lisa Levin]
Shares of American Woodmark Corporation (NASDAQ: AMWD) got a boost, shooting up 13 percent to $100.05 after the company reported upbeat Q4 results.
Hot Heal Care Stocks For 2019: Tortoise MLP Fund, Inc.(NTG)
Advisors' Opinion:- [By Shane Hupp]
Shares of Northgate plc (LON:NTG) have received an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is GBX 523.25 ($6.67).
Hot Heal Care Stocks For 2019: Arena Pharmaceuticals, Inc.(ARNA)
Advisors' Opinion:- [By ]
Arena Pharmaceuticals (Nasdaq: ARNA) has completed Phase 2 evaluation of its Ralinepag program for pulmonary arterial hypertension (PAH). The drug was granted orphan status by the U.S. Food and Drug Administration in 2014 which brings faster case review and increased patent protection.
- [By Stephan Byrd]
Partner Fund Management L.P. purchased a new position in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in the 2nd quarter, HoldingsChannel reports. The fund purchased 1,196,891 shares of the biopharmaceutical company’s stock, valued at approximately $52,184,000.
- [By Max Byerly]
New York State Common Retirement Fund increased its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 41.9% in the 1st quarter, Holdings Channel reports. The firm owned 51,175 shares of the biopharmaceutical company’s stock after acquiring an additional 15,115 shares during the period. New York State Common Retirement Fund’s holdings in Arena Pharmaceuticals were worth $2,021,000 as of its most recent SEC filing.
- [By Max Byerly]
Northern Trust Corp grew its stake in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 16.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 543,774 shares of the biopharmaceutical company’s stock after buying an additional 78,445 shares during the period. Northern Trust Corp owned 1.10% of Arena Pharmaceuticals worth $21,479,000 at the end of the most recent reporting period.
- [By ]
Arena Pharmaceuticals (ARNA) : "I like specialty pharma. This is a good one, too."
Dominion Energy (D) : "You have to buy it. It's time to think long-term."
- [By Max Byerly]
Macquarie Group Ltd. lifted its position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 4.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 490,000 shares of the biopharmaceutical company’s stock after buying an additional 20,900 shares during the period. Macquarie Group Ltd.’s holdings in Arena Pharmaceuticals were worth $21,364,000 as of its most recent SEC filing.
Hot Heal Care Stocks For 2019: MercadoLibre Inc.(MELI)
Advisors' Opinion:- [By Motley Fool Staff]
Dylan Lewis: Alright, Danny, turning our attention to a company that we both currently own, why don't we talk about MercadoLibre (NASDAQ:MELI)? I know this is one of your favorite businesses, it's one that you turned me onto, I think, about a year ago, and I've been following it since. Why don't we break down for people that aren't as familiar with the business?
- [By Dan Caplinger]
Latin American e-commerce giant MercadoLibre (NASDAQ:MELI) has capitalized on fundamental growth prospects for years. Sometimes, however, often-overlooked factors can hold back a stock. One trend that isn't sexy but has played a major yet often misunderstood role throughout first-quarter earnings season has been the newest accounting method from the Financial Accounting Standards Board with respect to revenue recognition, and MercadoLibre found itself in the crosshairs of the new standard's potential negative impact.
- [By Max Byerly]
Shares of Mercadolibre Inc (NASDAQ:MELI) were up 5% during trading on Wednesday . The company traded as high as $345.98 and last traded at $344.93. Approximately 1,663,902 shares traded hands during trading, an increase of 123% from the average daily volume of 744,905 shares. The stock had previously closed at $328.45.
- [By Motley Fool Staff]
We're coming down the home stretch. Here comes stock No. 4, the company MercadoLibre (NASDAQ:MELI). The ticker symbol is MELI. Again, a slight effort at trying to pronounce the name as a native speaker of Spanish might. This is a company that's a $13 billion company. It's one I've mentioned a number of times on this podcast. I'm sure, in some of our five-stock samplers, I've included it. I'm not looking at the full list right now. It's one of my favorite go-to companies.
- [By Shane Hupp]
Westpac Banking Corp raised its stake in MercadoLibre (NASDAQ:MELI) by 11.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,793 shares of the company’s stock after purchasing an additional 2,853 shares during the quarter. Westpac Banking Corp owned about 0.06% of MercadoLibre worth $9,905,000 at the end of the most recent quarter.
Hot Heal Care Stocks For 2019: Intec Pharma Ltd.(NTEC)
Advisors' Opinion:- [By Max Byerly]
Headlines about Intec Pharma (NASDAQ:NTEC) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.4513319646459 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Joseph Griffin]
Intec Pharma (NASDAQ:NTEC) has been assigned a $15.00 target price by Oppenheimer in a research note issued to investors on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 185.71% from the company’s current price.
- [By Max Byerly]
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Media stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intec Pharma earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6707447165993 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Hot Heal Care Stocks For 2019: Tronox Limited(TROX)
Advisors' Opinion:- [By Shane Hupp]
Tronox (OTCMKTS:TROX) had its target price lowered by equities research analysts at BMO Capital Markets to $13.00 in a report released on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the basic materials company’s stock. BMO Capital Markets’ target price indicates a potential upside of 0.93% from the company’s previous close.
- [By Maxx Chatsko]
Shares of Tronox (NYSE:TROX) jumped over 20% today after the company announced it had filed a joint motion with the U.S. Federal Trade Commission to delay the appeal schedule regarding the review of its proposed acquisition of Cristal. The move suggests the titanium dioxide manufacturer and the FTC are making progress toward a compromise over the acquisition of the Saudi-based chemicals producer, which has been under intense regulatory scrutiny for two years.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Tronox (TROX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Maxx Chatsko]
One factor contributing to the awful start to life as a publicly traded company is simply timing. Venator Materials stock listed on public exchanges just in time to catch the last few months of a multiyear bonanza for titanium dioxide stocks. Shares of Kronos Worldwide, Chemours, and Tronox Ltd (NYSE:TROX) all jumped by triple digits in the three-year period ending in 2017. That helped to soften the blow from their double-digit declines suffered so far in 2018, but the newcomer has no such history to hang its hat on.
No comments:
Post a Comment